A business case for drug discovery

Dinar Candy

23 min

Success & Inspiration

Description

This is the latest episode of the free DDW narrated podcast, “A business case for drug discovery", which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. <span style= "font-size: 12.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"> They are called “<a href= "https://www.ddw-online.com/a-deal-in-the-making-17640-202206/">A deal in the making</a>”, “<a href= "https://www.ddw-online.com/why-project-management-holds-the-key-to-efficient-drug-development-18193-202208/">Why project management holds the key to efficient drug development</a>”, and “<a href= "https://www.ddw-online.com/transcending-expectations-for-cell-gene-therapy-development-17788-202207/">Transcending expectations for cell & gene therapy development</a>”. In the first article, Drug Discovery World Editor Reece Armstrong looks at how a number of deals in pharma have sparked excitement in the industry. In the second article, Ian Hollingsworth, Associate Director of product development at Boyds, the global drug development consultancy, explains the benefits to the drug development lifecycle of building strong partnerships with external consultants, and when and how to get the best from them. </span

Uploader

luna_tree

Episodes

A business case for drug discovery

Dinar Candy

23:15